news

US and China should collaborate more to bring AI to healthcare

2
SHARES

New article says that to take full advantage of deep-learning solutions in healthcare, the US and China should collaborate, not compete.

In a new commentary article, titled ‘It Takes a Planet’, Eric Topol, MD, of Scripps Research and Kai-Fu Li, PhD, CEO of the China-based tech investment firm Sinovation Ventures have argued for more collaboration between China and the US on artificial intelligence (AI) development.

 

SECURE YOUR FREE SPOT

 


This webinar explores how the pharmaceutical industry can move towards sustainable autonomous operations.

Realising autonomous pharmaceutical operations | 9 February 2026 | 10am

What you’ll discover:

  • Understand the key drivers of the pharmaceutical industry and how autonomous operations are shaping its future and driving IT-OT conversion
  • Explore the value of automation in enhancing operational efficiency and driving business growth for life sciences
  • Gain expert insight on the potential benefits of implementing automation solutions.

Register now – it’s free

This comes in the wake of the US government ordering the AI company iCarbonX in China to divest its majority ownership stake in the Massachusetts-based company PatientsLikeMe.

“Chinese academics and companies already have unfettered access to personal health data,” they write. “To compete in AI health, US companies will need access to clinical data on a similar scale. How will that be possible if the current isolationist policy continues?”

Topol and Li continue that big data has changed the landscape of medicine, with every individual representing vast amounts of medical information that no human can adequately process. This is occurring at a time when there are unacceptable levels of medical errors, inefficiency, waste, burnout and depression among clinicians, and high costs for medical care.

They also note that poor access to medical care among people living in rural areas increases inequities in healthcare.

“These problems mandate big thinking on how we can pool our resources to promote better health everywhere and for everyone,” they continue. “We have at our fingertips technology capable of analysing petabytes of data. The difference now is that it is potentially achievable by capitalising on the ability to analyse the data rather than capitulating to the challenge.

“Let us embrace this opportunity by working together collaboratively across the planet for the greater good of all.”

The commentary article was published in Nature Biotechnology.

Share via
Share via